Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

In advanced hip OA, Depo-Medrone demonstrated significant relief of acute pain1
 

Mean change in Numerical Rating Scale (NRS)* scores over 8 weeks1

Full preview Mean change in Numerical Rating Scale (NRS)* scores over 8 weeks

Study design: A randomized controlled trial of patients with moderate to severe hip osteoarthritis, randomized 1:1:1:1 into four groups: non-injection group, normal saline (3 mL), non-animal stabilized hyaluronic acid (Durolane 3 mL/60 mg licensed for single injection) or methylprednisolone acetate (Depo-Medrone 3 mL/120 mg)β. The primary outcome measure was the NRS* score for worst pain. The secondary outcome measures were the Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain and function global scores, patient global assessment and Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT)-Osteoarthritis Research Society International (OARSI) responder criteria. Assessments were performed at baseline, weeks 1, 4, 8, and when possible week 16 post-injection.1

  • Depo-Medrone demonstrated significant improvement from baseline in WOMAC pain and function global scores1
    - Effect sizes indicated the benefit of Depo-Medrone was substantial in improving NRS pain scores and WOMAC pain and function scores from baseline1
     
  • Depo-Medrone was well tolerated during the treatment period1

In analyses of clinical studies by AHRQ
Patients with early RA receiving low-dose corticosteroids plus DMARD therapy versus patients receiving DMARD therapy alone showed:
 

  • Significantly less radiographic progression (over 1-2 years)2
  • Better remission (DAS <2.6) scores2
  • Greater improvements in functional capacity and less work disability2
     

In a head-to-head trial vs triamcinolone hexacetonide (THA)

Depo-Medrone: significant improvement of inflammation-related OA knee pain3
 

Significant improvement in Visual Analogue Scale (VAS) compared with THA3

Full preview Significant improvement in Visual Analogue Scale (VAS) compared with THA

Study design: Randomized, double-blind comparative study in hospital-referred patients with symptomatic, radiographic knee OA (N=57). Patients were randomized to either intra-articular THA (Lederspan) 20 mg or intra-articular methylprednisolone acetate (Depo-Medrone) 40mg. Primary endpoints were changes in VAS, stair climb time (SCT),  and Lequesne index score (LEQ) at weeks 3 and 8.3

Adapted from Pyne et al 2004.

  • Depo-Medrone was similar to THA in delivering significant improvement in pain (VAS) and disability LEQ at week 33

    - Only Depo-MedroneL maintained significant improvement in both measures at week 8 (P<.05)3
     
  • In additional analyses, Depo-Medrone also improved postoperative recovery in knee OA and significantly reduced the incidence and severity of cartilage erosions4,


Depo-Medrone demonstrated rapid and sustained relief of shoulder pain due to subacromial bursitis5

  • Depo-Medrone delivered similar mean pain relief (61%) to triamcinolone (TMC) at 2 weeks5

Change in VAS after injection

Full preview Change in VAS after injection

Study design: Randomized, prospective, double-blind comparative study in ambulatory patients (N=24) with shoulder pain due to subacromial bursitis and/or partial or full-thickness rotator cuff tears. Patients were randomized to an injection of 1 mL (40 mg) of Depo-Medrone or TMC, both without lidocaine. Range of motion (ROM) and VAS in shoulder pain was registered after 10 and 30 minutes, as well as after 1 and 2 weeks postinjection.5

  • More patients in the Depo-Medrone group sustained pain relief (VAS) of 50% or more 2 weeks post injection (P=.02)5
  • Depo-Medrone also improved ROM by a mean of 33%, comparable to TMC5
  • Patients treated with Depo-Medrone experienced more rapid pain relief than patients receiving TMC5

*NRS is calculated on a pain scale of 0-101.
† Effect size was calculated as the mean change from baseline divided by the baseline SD1.
 Agency for Healthcare Research and Quality (Department of Health and Human Services).
β Suggested dosage in Depo-Medrone SPC for a large joint (knee, ankle, shoulder): 20 – 80 mg.

References

  1. Atchia I, Kane D, Reed MR, et al. Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. Ann Rheum Dis. 2011;70:110-116. 
  2. Donahue KE, Jonas DE, Hansen RA, et al. Drug therapy for rheumatoid arthritis in adults: an update. Agency Health Res Qual. 2012. ARQ Publication No. 12 EHC025-EF. 
  3. Pyne D, Ioannou Y, Mootoo R, Bhanji A. Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate. Clin Rheumatol. 2004;23:116-120. 
  4. Koyonos L, Yanke AB, McNickle AG, et al. A randomized, prospective, double-blind study to investigate the effectiveness of adding Depo-Medrol to a local anesthetic injection in postmeniscectomy patients with osteoarthritis of the knee. Am J Sports Med. 2009;37(6):1077-1082.
  5. Chávez-López MA, Navarro-Soltero LA, Rosas-Cabral AR, et al. Methylprednisolone versus triamcinolone in painful shoulder using ultrasound-guided injection. Mod Rheum. 2009;19:147-150.